August 29, 2025 — Leads & Copy — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced that its senior leadership is scheduled to present at two upcoming conferences: the 2025 Wells Fargo Healthcare Conference in Boston on September 5, 2025, at 8:00 a.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025, at 11:00 a.m. ET. Webcasts will be available.
Iovance Biotherapeutics, Inc. aims to be a global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company is pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication.
Investors can contact Iovance Biotherapeutics via IR@iovance.com or 650-260-7120 ext. 150. Media inquiries can be directed to PR@iovance.com or 650-260-7120 ext. 150.
Contact:
IR@iovance.com
650-260-7120 ext. 150
PR@iovance.com
650-260-7120 ext. 150
Source: Iovance Biotherapeutics, Inc.
